Cediranib

Across CCLE and GDSC cell-line panels, response to Cediranib is significantly associated with the mutation status of multiple genes, with LUNG_NSCLC_LUSC cell lines showing a particularly strong set of associations.

The most reproducible Cediranib response-associated genes across cancer lineages are LRP1B, PKHD1L1, and COL11A1, each associated with drug response in up to 3 lineages. Since the analysis identifies associations rather than directional relationships, both response-to-biomarker and biomarker-to-response views are provided.

Each biomarker is linked to its corresponding Q-omics profile. The box plot shows the strongest observed association, Cediranib response grouped by LRP1B status in LUNG_NSCLC_LUSC.

Mutation status biomarkers of Cediranib response

Ranked by combined sampling and lineage consensus. X-score (response→biomarker) and Y-score (biomarker→response) are standardized regression coefficients; both directions are reported because the association is undirected. The reported p-values are derived from the association test.

Lineage	Partner gene	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
LUNG_NSCLC_LUSC	LRP1B →	-2.584	-0.564	.040	.023	3	3
LUNG_NSCLC_LUAD	PKHD1L1 →	-2.169	-0.355	.020	.027	3	3
LUNG_SCLC	COL11A1 →	-2.321	-0.503	.010	.001	3	3
BLOOD_Lymphoma	CSPG4 →	-2.719	-0.345	.039	.006	3	2
LUNG_SCLC	CSMD3 →	-1.378	-0.330	.014	.026	3	2
LUNG_NSCLC_LUAD	PCLO →	-3.169	-0.405	.008	.012	3	2

Each biomarker links to its Q-omics profile. Showing the 6 strongest associations by consensus.

Cediranib response by LRP1B status — LUNG_NSCLC_LUSC

Explore this box plot interactively →